Please Scroll Down to See Forums Below 
210toosmall
New member
what is usual dosage?
just to keep estro in check
ed eod etc....
k 4 help!
just to keep estro in check
ed eod etc....
k 4 help!
letrozole
- Thread starter 210toosmall
- Start date
NJjuice22
New member
How many milligrams of test are you using? Letro is usually 2.5mg/cc, if your using 500mg of test or under you can get away with 1/2 cc ed or eod depending on how prone you are to esstrogen sides...i dont get really puffy on test and I dont get bad gyno so I usually just do 1.25mg EOD because i never go over 500mg of test...try that and see how it goes, if you notice any water rentenion or itchy nips, bump it up to 1/2cc (1.25mg) every day.
ericahls
New member
210toosmall said:
It all depends on what you are taking. It won't help with Tren or Deca for example. That said Letrozole is very strong and if you’re using reasonable dosages of aromatizable drugs like test or dbol .75 - 1.25 mg / day of Letrozole should be plenty.
Do not continue to use Letrozole into your PCT. It is too strong and will trash your Lipid profiles.
210toosmall
New member
ericahls said:
sorry bro,
You must spread some Karma around before giving it to ericahls again.
hammercurls
New member
your WRONG about lipids...its armidex that trashes them.. please stop posting nonsense
ericahls
New member
hammercurls said:
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM.
Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. [email protected]
BACKGROUND: The newer generation, nonsteroidal aromatase inhibitors (AIs) anastrozole and letrozole have shown superior efficacy compared with tamoxifen as first-line treatments and compared with megestrol acetate as second-line therapy in postmenopausal women with advanced breast carcinoma. In an open-label, Phase II trial, it was reported that exemestane showed numerical superiority compared with tamoxifen for objective response and clinical benefit. Because these agents ultimately may be administered for periods of up to 5 years in the adjuvant setting, it is of increasing importance to assess their tolerability and pharmacologic profiles. METHODS: In the absence of data from direct clinical comparisons, the published literature was reviewed for the clinical pharmacology, pharmacokinetic characteristics, and selectivity profiles of anastrozole, letrozole, and exemestane. RESULTS: At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) were 41-48 hours, 2-4 days, and 27 hours, respectively. The time to steady-state plasma levels was 7 days for both anastrozole and exemestane and 60 days for letrozole. Androgenic side effects have been reported only with exemestane.
Anastrozole treatment had no impact on plasma lipid levels, whereas both letrozole and exemestane had an unfavorable effect on plasma lipid levels. In indirect comparisons, anastrozole showed the highest degree of selectivity compared with letrozole and exemestane in terms of a lack of effect on adrenosteroidogenesis. CONCLUSIONS: All three AIs demonstrated clinical efficacy over preexisting treatments. However, there were differences in terms of pharmacokinetics and effects on lipid levels and adrenosteroidogenesis. The long-term clinical significance of these differences remains to be elucidated. Copyright 2002 American Cancer Society.This is exactly what can happen when you stop taking your MEDS.
Any questions hammercurls
????????????????????????
Last edited:
hammercurls
New member
ericahls said:
for you--------->
Similar threads
